Table 3.
Pathways to triple therapy split by mMRC score
| Treatment pathway from date of COPD diagnosis | mMRC score
|
||||
|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | 4 | |
| n (%) | n (%) | n (%) | n (%) | n (%) | |
| ICS + LABA → ICS + LABA + LAMA | 59 (24) | 347 (23) | 231 (25) | 182 (29) | 50 (25) |
| ICS + LABA + LAMA | 25 (10) | 156 (11) | 90 (10) | 48 (8) | 22 (11) |
| ICS → ICS + LABA → ICS + LABA + LAMA | 20 (8) | 131 (9) | 79 (8) | 60 (10) | 20 (10) |
| None → ICS + LABA → ICS + LABA + LAMA | 23 (9) | 96 (7) | 78 (8) | 55 (9) | 16 (8) |
| SABA → ICS + LABA → ICS + LABA + LAMA | 9 (3.6) | 78 (5) | 43 (4.6) | 26 (4.1) | 5 (2.5) |
| None → ICS + LABA + LAMA | 11 (4.4) | 66 (4.4) | 33 (3.5) | 31 (4.9) | 9 (4.5) |
| None → LAMA → ICS + LABA + LAMA | 15 (6) | 63 (4.2) | 39 (4.2) | 27 (4.3) | 3 (1.5) |
| None → ICS → ICS + LABA → ICS + LABA + LAMA | 9 (3.6) | 52 (3.5) | 36 (3.8) | 16 (2.5) | 5 (2.5) |
| LAMA → ICS + LABA + LAMA | 7 (2.8) | 58 (3.9) | 25 (2.7) | 13 (2.1) | 4 (2.0) |
| SABA → ICS → ICS + LABA → ICS + LABA + LAMA | 6 (2.4) | 34 (2.3) | 28 (3.0) | 16 (2.5) | 7 (3.5) |
| SABA + SAMA → ICS + LABA → ICS + LABA + LAMA | 2 (0.8) | 42 (2.8) | 21 (2.2) | 16 (2.5) | 9 (4.5) |
| SABA → LAMA → ICS + LABA + LAMA | 10 (4.0) | 28 (1.9) | 26 (2.8) | 9 (1.4) | 4 (2.0) |
| ICS → ICS + LAMA → ICS + LABA + LAMA | 2 (0.8) | 25 (1.7) | 18 (1.9) | 15 (2.4) | 6 (3.0) |
| ICS → ICS + LABA + LAMA | 7 (2.8) | 28 (1.9) | 8 (0.9) | 4 (0.6) | 3 (1.5) |
| ICS + LAMA → ICS + LABA + LAMA | 0 (0) | 27 (1.8) | 14 (1.5) | 5 (0.8) | 1 (0.5) |
| LABA → ICS + LABA → ICS + LABA + LAMA | 4 (1.6) | 15 (1.0) | 7 (0.7) | 12 (1.9) | 2 (1.0) |
| None → LABA → ICS + LABA → ICS + LABA + LAMA | 1 (0.4) | 16 (1.1) | 10 (1.1) | 7 (1.1) | 4 (2.0) |
| Other non-frequent pathways | 41 (16) | 223 (15) | 150 (16) | 90 (14) | 31 (15) |
| Total | 251 (100) | 1,485 (100) | 936 (100) | 632 (100) | 201 (100) |
Notes: Pathways with a percent frequency of less than 1% were grouped under the category “other non-frequent pathways”. The first drug listing in the treatment pathway was considered to be the patient’s initial therapy, and the second drug listing was the prescription after the initial date of COPD diagnosis. All percent values >5.0 were rounded up.
Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; mMRC, modified Medical Research Council; SABA, short-acting β2-agonist; SAMA, short-acting muscarinic antagonist.